Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 11/20 | 0.52 |
| ▸ | PDE1A | P54750 | 3/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.50 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468608 | 1.00 | NPBWR1 (0.52) | NPBWR1PDE1APDE1BPDE1CMCHR1 | |
| SCHEMBL30667947 | 0.88 | PDE1A (0.48) | NPBWR1PDE1APDE1BPDE1CMCHR1 | |
| SCHEMBL1943995 | 0.80 | LMNA (0.54) | NPBWR1PDE1APDE1BPDE1CMCHR1 | |
| SCHEMBL30731296 | 0.80 | NPBWR1 (0.52) | NPBWR1PDE1APDE1BPDE1CMCHR1 | |
| SCHEMBL15545682 | 0.80 | NPBWR1 (0.52) | NPBWR1PDE1APDE1BPDE1CMCHR1 | |
| SCHEMBL16014472 | 0.79 | PDE1A (0.50) | NPBWR1PDE1APDE1BPDE1CMCHR1 | |
| SCHEMBL10195525 | 0.78 | HSP90AA1 (0.60) | NPBWR1PDE1APDE1BPDE1CMCHR1 | |
| SCHEMBL16014436 | 0.78 | PDE1A (0.51) | NPBWR1PDE1APDE1BPDE1CMCHR1 | |
| SCHEMBL19953369 | 0.77 | PDE1A (0.50) | NPBWR1PDE1APDE1BPDE1CMCHR1 | |
| SCHEMBL29514413 | 0.77 | PDE1B (0.50) | NPBWR1PDE1APDE1BPDE1CMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3964518-B1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| EP-4272836-A2 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4272836-A2 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116715700-A | CD73 inhibitor, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-3399984-B1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-113366008-B | CD73 inhibitor, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220162253-A1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-3964518-A1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2022-03-09 | — | — | EP | disclosed |
| EP-2970198-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES FOR USE AS ALDOSTERONE SYNTHASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| EP-2964628-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP1 1 B2 OR CYP1 1 B1 ) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| EP-2964646-A1 | NOVEL PYRAZOL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20150376192-A1 | NOVEL PYRAZOL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376192-A1 | NOVEL PYRAZOL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376192-A1 | NOVEL PYRAZOL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014139981-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES FOR USE AS ALDOSTERONE SYNTHASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014135507-A1 | NOVEL PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135561-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP1 1 B2 OR CYP1 1 B1 ) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135507-A1 | NOVEL PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162253-A1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ENTPD5, ENTPD1, NT5E | NPBWR1 3056/4885PDE1A 339/4885PDE1B 328/4885 |
| US-20150376192-A1 | NOVEL PYRAZOL DERIVATIVES | CYP3A43, ADRB3, UGT1A3 | NPBWR1 1649/4885PDE1A 1574/4885PDE1B 1434/4885 |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NPBWR1 3085/4885PDE1A 844/4885PDE1B 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.